⌘K

MGEN

NASDAQ

Miragen Therapeutics, Inc.

SectorHealth CareIndustryMedical SpecialitiesIPO2014

News25/Ratings0

Latest news

25 items

1865d13D/G
SEC Form SC 13G/A filed by Miragen Therapeutics, Inc.
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
1870d13D/G
SEC Form SC 13G filed
SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
1889d13D/G
SEC Form SC 13G filed
SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
1892d13D/G
SEC Form SC 13G/A filed
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
1892d13D/G
SEC Form SC 13G/A filed
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
1900dINSIDER
SEC Form 4 filed by L Joseph Turner
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1900dINSIDER
SEC Form 4 filed by Evan Peter Harwin
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1900dINSIDER
SEC Form 4 filed by S. Jeffrey Hatfield
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1900dINSIDER
SEC Form 4 filed by Tomas Kiselak
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1900dINSIDER
SEC Form 4 filed by Arlene Morris
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1918dINSIDER
SEC Form 3 filed by Barrett Katz
3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1918dINSIDER
SEC Form 4 filed by Barrett Katz
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1919dINSIDER
SEC Form 4 filed by A. Jason Leverone
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1919dINSIDER
SEC Form 4 filed by Jonathan Violin
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1919dSEC
SEC Form 8-K filed
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
1920dINSIDER
SEC Form 4 filed by Diana Escolar
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1920dINSIDER
SEC Form 4 filed by M. Lee Rauch
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
1920dSEC
SEC Form SC 13G filed
SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
1920dPR
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”). Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VR
1924dSEC
SEC Form 4 filed by Stuart William Marshall
4 - MIRAGEN THERAPEUTICS, INC. (0001590750) (Issuer)
1928dSEC
SEC Form SC 13G filed
SC 13G - MIRAGEN THERAPEUTICS, INC. (0001590750) (Subject)
1928dSEC
SEC Form SC 13G filed
SC 13G - MIRAGEN THERAPEUTICS, INC. (0001590750) (Subject)
1932dSEC
SEC Form SC 13G filed
SC 13G - MIRAGEN THERAPEUTICS, INC. (0001590750) (Subject)
1934dSEC
SEC Form SC 13D filed
SC 13D - MIRAGEN THERAPEUTICS, INC. (0001590750) (Subject)
1935dSEC
SEC Form 8-K filed
8-K - MIRAGEN THERAPEUTICS, INC. (0001590750) (Filer)